EQS-News: Marinomed Biotech AG / Key word(s): Agreement Marinomed Biotech AG announces agreement with the European Investment Bank (EIB) for an 18-month deferral of repayments for the venture loan from 2019 03/28/2024 / 07: 45 CET/CEST The issuer/publisher is responsible for the content of the message. ═════════════════════════════════════════ ═════════ Marinomed Biotech AG issues agreement with the European Investment Bank (EIB) for an 18-month deferral of repayments for the venture loan announced in 2019 • The agreement with the EIB provides for a deferral of all capital repayments for 18 months; interest rates remain unchanged • Property financing lenders also agreed to suspend repayments for 18 months • Marinomed plans to achieve key milestones in 2024, including further deals for the Marinosolv platform Korneuburg, Austria, March 28, 2024 – The Marinomed Biotech AG (VSE:MARI) has reached an agreement with the European Investment Bank (EIB) to defer repayments of the EUR 15 million venture loan granted in 2019. Accordingly, the repayment of the first tranche in the nominal amount of EUR 4 million will be postponed from October 2024 to April 2026. The second tranche with a nominal value of EUR 5 million will now fall due in June 2027 instead of December 2025. Marinomed will repay the third tranche with an outstanding nominal amount of EUR 4.7 million in semi-annual installments of EUR 0.67 million between December 2025 and August 2028. Interest rates remain unchanged. The agreements contain additional conditions, including the extension of the existing royalty agreement for five years. The real estate lenders also agreed to suspend their capital repayments together with the EIB. “The financing agreement with the EIB has enabled us to make significant progress in our product developments in the areas of virology and immunology. We appreciate the commitment to suspend repayments until we can realize the commercialization of our assets. We are working to close additional partnerships for our Marinosolv product candidates this year. At the same time, we are also continually expanding our Carragelose business, most recently with the sales partnerships for Eastern Europe and the Gulf region. Our collaboration with Procter & Gamble in the USA is also gaining momentum. We are confident that our ongoing initiatives will generate sufficient cash flow to adequately service the company’s financing needs and our liabilities,” comments Pascal Schmidt, CFO of Marinomed. About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotechnology company with a growing development pipeline and globally marketed therapeutics. The company develops patent-protected, innovative products in the therapeutic areas of immunology and virology based on its Marinosolv® platform and the virus-blocking effect of Carragelose®. The Marinosolv® technology increases the solubility and bioavailability of poorly soluble active ingredients and is used to develop new therapeutics for indications in the area of autoreactive immune diseases. The Virology segment includes Carragelose®-based over-the-counter products for the prevention and treatment of viral upper respiratory tract infections, partnered in more than 40 countries. The company is based in Korneuburg, Austria and is listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information: (1) https://www.marinomed.com. Inquiry note Marinomed Biotech AG International media inquiries PR & IR: Lucia Ziegler Metrum Communications: Eva Ruppnig T: +43 2262 90300 158 T: +43 664 4065744 E-mail: (2)pr@marinomed.com E-Mail: (4)marinomed@metrum.at E-Mail: (3)ir@marinomed.com Disclaimer This press release contains forward-looking statements that are based on current views, expectations and forecasts of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described or otherwise expressed or implied by such statements. The current views, expectations and forecasts of the management of Marinomed Biotech AG are influenced by the context of such statements or words as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and Recognize “target”. Forward-looking statements speak only as of the date on which they are made. Marinomed Biotech AG undertakes no obligation to update, revise or revise any forward-looking statements contained in this press release, whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are brands of Marinomed AG. The brands are the property of Marinomed Biotech AG or are licensed out to partners in selected countries. ═════════════════════════════════════════ ═════════ ════════════════════════ 03/28/2024 CET/CEST Publication of a corporate news/financial announcement, transmitted by EQS Group AG. www.eqs.com
═════════════════════════════════════════ ═════════ ════════════════════════ Language: German Company: Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria Telephone: +43 2262 90300 Email: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6 WKN: A2N9MM Stock exchanges: open market in Berlin, Düsseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (official trading) EQS News ID: 1869189 End of message EQS News Service 1869189 03/28/2024 CET/CEST References Visible links 1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=1869189&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. pr@marinomed.com 3. and@marinomed.com
4. marinomed@metrum.at